Skip to Content

Bausch Health Companies Inc BHC

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat




Bausch Health Reports Painful Q2 From Pandemic Shock, Reveals Bold Plan to Spin Off Eye Health

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Bausch Health had a tough second quarter, with business hampered by the COVID-19 pandemic, though earnings were overshadowed by the major announcement that the firm will spin off its Bausch+Lomb eye health unit, which accounts for nearly 45% of the business. We are maintaining our $23 fair value estimate, with lower-than-expected revenue through the year being offset by hints of positive market share trends in liquid eyecare solutions and intraocular lenses.

Read Full Analysis

Company Profile

Business Description

Bausch Health Companies Inc is a company whose mission is to improve people's lives with its health care products. The company develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, in the therapeutic areas of eye health, gastroenterology and dermatology. It is delivering on its commitments as it builds an company dedicated to advancing global health.

2150 Saint Elzear Boulvard West
Laval, QC, H7L 4A8, Canada
T +1 514 744-6792
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 21,700